摘要
套细胞淋巴瘤（MCL）占全部成人非霍奇金淋巴瘤（NHL）的4％～6％。常见于老年人，男性多于女性（2～3）：1，诊断时平均年龄为54～68岁，60％～70％的患者确诊时已为AnnArbor Ⅳ期。MCL瘤细胞免疫表型为CD5（＋），CD20（＋），CD23（-），CD10（-），具有特征性的t（11；14）（q13；q32）细胞遗传学改变，并导致其基因产物cyclin D1过表达。MCL虽对诱导化疗敏感，但多在短时间内出现疾病进展，中位存活时间仅3年左右，尚无有效的治愈方法。因此，MCL在各类型淋巴瘤中预后最差，迫切需要探索新的方法来提高其疗效。
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2006年第10期710-712,共3页
Chinese Journal of Hematology
参考文献19
-
1Ghielmini M,Schmitz SF,Cogliatti S,et al.Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma:a study of the Swiss Group for Clinical Cancer Research (SAKK).J Clin Oncol,2005,23:705-711.
-
2Coiffier B,Haioun C,Kctterer N,et al.Rituximab (Anti-CD20 Monoclonal Antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:a multicenter phase Ⅱ study.Blood,1998,92:1927-1932.
-
3Lenz G,Dreyling M,Hoster E,et al.Immunochemotherapy with rituximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma:results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).J Clin Oncol,2005,23:1984-1992.
-
4Howard OM,Gribben JG,Neuberg DS,et al.Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma:molecular complete responses are not predictive of progression-free survival.J Clin Oncol,2002,20:1288-1294.
-
5Forstpointner R,Dreyling M,Repp R,et al.The addition of rituximab to a combination of fludarabine,cyclophosphamide,mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.Blood,2004,104:3064 -3071.
-
6Romaguera JE,Fayad L,Rodriguez MA,et al.High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.J Clin Oncol,2005,23:7013-7023.
-
7Andersen NS,Pedersen L,Elonen E,et al.Primary treatment with autologous stem cell transplantation in mantle cell lymphoma:outcome related to remission pretransplant.Eur J Haematol,2003,71:73 -80.
-
8Dreyling M,Lenz G,Hoster E,et al.Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma:results of a prospective randomized trial of the European MCL Network.Blood,2005,105:2677-2684.
-
9Mangel J,Leitch HA,Connors JM,et al.Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to eonventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma:a matched pair analysis.Ann Oncol,2004,15:283 -290.
-
10Gianni AM,Magni M,Martelli M,et al.Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).Blood,2003,102:749-755.
同被引文献35
-
1Banks PM, Chan J, Cleary ML, et al, Mantle cell lymphoma. ;A proposal for unification of morphologic, immunologic, and molecular data[J], Am J Surg Pathol, 1992 , 16 (7):637-640.
-
2Marce S, Balague O, Colomo L,et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy[J]. Clin Cancer Res, 2006, 12 (12): 3754- 3761.
-
3Schrader C, Meusers P, Brittinger G, et al. Topoisomerase IIa expression in mantle cell lymphoma:a marker of cell proliferation and a prognostic factor for clinical outcome[J]. Leukemia, 2004,18 (7):1200-1206.
-
4Joshua B, Ranjana A. Treatment of mantle cell lymphoma:Current approach and future directions[J]. Critical Reviews in Oncology/Hematology, 2006,58 (3) :257-265.
-
5Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients[J]. Leukemia &. Lymphoma, 21100 , 39 (1-2): 77-85.
-
6Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macro globulinemia, and mantle-cell lymphoma[J].J Clin Oncol,1999,17 (2):546-553.
-
7Tobinai K, Watanabe T, Ogura M, et al. Phase II study of o ral fludarabine phosphate in relapsed indolent B-Cell non Hodgkin's lymphoma[J]. J Clin Oncol , 2006 , 24 ( 1 ) : 174- 180.
-
8Foran JM, Rohatiner AZ, Cunningham D, et al. European phase Ⅱ study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lym phoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma[J]. J Clin Oncol, 2000,18 (2) :317-324.
-
9Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of singleagent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)[J]. J Clin Oncol, 2005, 23 (4): 705-711.
-
10Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincris tine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lym phoma Study Group (GLSG)[J]. J Clin Oncol ,2005,23 (9) :1984-1992.
引证文献3
-
1臧健,李晨,任道凌,易成.套细胞淋巴瘤的治疗进展[J].肿瘤防治研究,2008,35(6):453-456. 被引量：3
-
2马寒,童秀珍,苏畅,李娟,陆春.累及皮肤的套细胞淋巴瘤一例[J].中华皮肤科杂志,2012,45(8):592-594. 被引量：1
-
3周仕霞,张力,李晓明,唐君玲,无.Jeko-1细胞株中边群细胞的免疫表型、干细胞基因和集落形成能力的生物学特点[J].中国实验血液学杂志,2020,28(5):1558-1562. 被引量：1
二级引证文献5
-
1贾文霞.纳米医学诊断与治疗技术研究新进展[J].中国医药导报,2013,10(6):25-27. 被引量：8
-
2丁凌芳.1例套细胞淋巴瘤患者行自体造血干细胞移植的护理[J].内蒙古中医药,2014,33(14):146-147.
-
3权哲,李莹,化范例,梅莉红,王红枫,曾义斌,干慧慧,方芳.累及皮肤的套细胞淋巴瘤一例[J].中华皮肤科杂志,2015,48(1):50-52.
-
4刘悦,陈延峰,许宁,蔡路德,赵燕芳.Btk抑制剂依鲁替尼的合成工艺改进[J].中国药物化学杂志,2017,27(4):288-291. 被引量：5
-
5高海枝.沙利度胺联合R-GEMOX方案治疗复发性套细胞淋巴瘤的生存率及生活质量研究[J].药品评价,2022,19(19):1180-1183.
-
1姜靖雯,陈学武.结直肠癌可切除肝转移灶的术前化疗文献复习[J].癌症进展,2015,13(4):388-390.
-
2屈娜,陈元.表皮生长因子受体抑制剂在非小细胞肺癌中的研究进展[J].癌症进展,2010,8(5):453-457.
-
3王业伟,黄文君(综述),方美云(审校).套细胞淋巴瘤的治疗进展[J].国际输血及血液学杂志,2010,33(2):158-162. 被引量：1
-
4李志欣,吴立华,梁学刚,杨奋有.中晚期肝癌的综合性治疗[J].现代中西医结合杂志,2012,21(9):1020-1022.
-
5警惕15种癌症信号[J].健康管理,2012(5):42-43.
-
6顾俊骏,柏愚,李兆申.晚期胰腺癌的化疗[J].中华胰腺病杂志,2008,8(3). 被引量：1
-
7隋翔宇,胡三元.胃肠间质瘤诊断及治疗研究进展[J].山东医药,2015,55(12):106-108. 被引量：5
-
8男女身上发出的15个癌症信号[J].现代养生,2015,0(3):38-39.
-
9胡涵光,袁瑛.胰腺癌的内科治疗规范与进展[J].肝胆胰外科杂志,2015,27(6):459-463. 被引量：1
-
10黄广建.手术切除胃癌的肝转移灶:22例的17年分析[J].国外医学（外科学分册）,2004,31(1):59-60.
